Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 5/20 | 0.72 |
| ▸ | CTSB | P07858 | 3/20 | 0.72 |
| ▸ | CTSS | P25774 | 1/20 | 0.72 |
| ▸ | CTSK | P43235 | 1/20 | 0.72 |
| ▸ | TACR1 | P25103 | 2/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15627733 | 1.00 | CTSL (0.72) | CTSLCTSBCTSSCTSKTACR1 | |
| SCHEMBL13924735 | 0.95 | CTSL (0.66) | CTSLCTSBCTSSCTSKTACR1 | |
| SCHEMBL10706786 | 0.91 | HDAC8 (0.68) | CTSLCTSBCTSSCTSKTACR1 | |
| SCHEMBL8014485 | 0.90 | CAPN1 (0.72) | CTSLCTSBCTSSCTSK | |
| SCHEMBL6801635 | 0.88 | CTSL (0.66) | CTSLCTSBCTSSCTSKTACR1 | |
| SCHEMBL6801020 | 0.88 | CTSL (0.58) | CTSLCTSBCTSSCTSKTACR1 | |
| SCHEMBL3478166 | 0.88 | CTSL (0.58) | CTSLCTSBCTSSCTSKTACR1 | |
| SCHEMBL10349206 | 0.88 | CTSL (0.64) | CTSLCTSBCTSSCTSKTACR1 | |
| SCHEMBL3478169 | 0.88 | CTSL (0.58) | CTSLCTSBCTSSCTSKTACR1 | |
| SCHEMBL6801630 | 0.88 | CTSL (0.66) | CTSLCTSBCTSSCTSKTACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220202777-A1 | AMIDE DERIVATIVES OF N-UREA SUBSTITUTED AMINO ACIDS AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS | ALLERGAN, INC. | 2022-06-30 | — | — | US | disclosed |
| US-9974772-B2 | Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators | ALLERGAN, INC. (US) | 2018-05-22 | — | — | US | disclosed |
| US-20170119737-A1 | AMIDE DERIVATIVES OF N-UREA SUBSTITUTED AMINO ACIDS AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS | ALLERGAN, INC. | 2017-05-04 | — | — | US | disclosed |
| US-20120071383-A1 | LIQUID DETERGENT COMPOSITION WITH ABRASIVE PARTICLES | THE PROCTER & GAMBLE COMPANY | 2012-03-22 | — | — | US | disclosed |
| EP-0543858-B1 | BENZIMIDAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND APPLICATION | BRITISH BIOTECH PHARM (GB) | 2000-12-20 | — | — | EP | disclosed |
| EP-0784629-A1 | PEPTIDYL COMPOUNDS AND THEIR THERAPEUTIC USE AS INHIBITORS OF METALLOPROTEASES | Chiroscience Limited (GB) | 1997-07-23 | — | — | EP | disclosed |
| WO-1996011209-A1 | PEPTIDYL COMPOUNDS AND THEIR THERAPEUTIC USE AS INHIBITORS OF METALLOPROTEASES | CHIROSCIENCE LIMITED (GB) | 1996-04-18 | — | — | WO | disclosed |
| US-5451676-A | Treatment of hypotension and bronchoconstriction | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1995-09-19 | — | — | US | disclosed |
| US-5274094-A | Diseases or conditions mediated by platelet-activating factor; cyclization of a diamino compound with a carboxylic acid | BRITISH BIO-TECHNOLOGY LIMITED (GB) | 1993-12-28 | — | — | US | disclosed |
| EP-0543858-A1 | BENZIMIDAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND APPLICATION | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1993-06-02 | — | — | EP | disclosed |
| US-5200412-A | Antiinflammatory agents and antiallergens | BRITISH BIO-TECHNOLOGY LIMITED (GB) | 1993-04-06 | — | — | US | disclosed |
| WO-1992003423-A1 | BENZIMIDAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND APPLICATION | BRITISH BIO-TECHNOLOGY LIMITED (GB) | 1992-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170119737-A1 | AMIDE DERIVATIVES OF N-UREA SUBSTITUTED AMINO ACIDS AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS | FPR1, FPR3, FPR2 | CTSL 662/4885CTSB 2374/4885CTSS 2761/4885 |
| US-20220202777-A1 | AMIDE DERIVATIVES OF N-UREA SUBSTITUTED AMINO ACIDS AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS | FPR1, FPR3, FPR2 | CTSL 662/4885CTSB 2374/4885CTSS 2761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.